Native and recombinant interleukin-2, two functionally distinct molecules

Molecular Immunology

Volumn 40, Issue 5, 2003, Pages 279-286

  Denis, Maria C ^a,b   Huber, Brigitte T ^a  

^a TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

Author keywords

Cellular activation; Cellular proliferation; Human; IL 2; T lymphocyte

Indexed keywords

ANTIGEN; CYTOKINE; INTERLEUKIN 2; INTERLEUKIN 2 RECEPTOR; RECOMBINANT CYTOKINE;

ALPHA CHAIN; ARTICLE; BINDING AFFINITY; BIOCHEMISTRY; CELLULAR IMMUNITY; CYTOKINE PRODUCTION; CYTOKINE RELEASE; HUMAN; HUMAN CELL; LYMPHOCYTE PROLIFERATION; MOLECULE; PROKARYOTE; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN MODIFICATION; SIGNAL TRANSDUCTION; T LYMPHOCYTE;

PROKARYOTA;

EID: 0042928151     PISSN: 01615890     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0161-5890(03)00102-0     Document Type: Article

References (44)

1. Anderson J.A., Lentsch A.B., Hadjiminas D.J., Miller F.N., Martin A.W., Nakagawa K., Edwards M.J. The role of cytokines, adhesion molecules, and chemokines in interleukin-2-induced lymphocytic infiltration in C57BL/6 mice. J. Clin. Invest. 97:1996;1952-1959.
2. Bich-Thuy L.T., Dukovich M., Peffer N.J., Fauci A.S., Kehrl J.H., Greene W.C. Direct activation of human resting T cells by IL 2: the role of an IL 2 receptor distinct from the Tac protein. J. Immunol. 139:1987;1550-1556.
3. Conradt H.S., Hauser H., Lorenz C., Mohr H., Plessing A. Post-translational modification of interleukin-2 is a late event during activation of human T lymphocytes by ionophore A23187 and phorbol ester. Biochem. Biophys. Res. Commun. 150:1988;97-103.
4. Dillman R.O. What to do with IL-2? Cancer Biotherap. Radiopharm. 14:1999;423-434.
5. Epling-Burnette P.K., Wei S., Liu J.H., Pericle F., Ussery D., Russell S.M., Leonard W.J., Djeu J.Y. Expression of interleukin-2 receptor gamma on human monocytes: characterization of lineage specific post-translational modifications. Eur. J. Immunol. 25:1995;291-294.
6. Frasier-Scott K., Hatzakis H., Seong D., Jones C.M., Wu K.K. Influence of natural and recombinant interleukin-2 on endothelial cell arachidonate metabolism: induction of de novo synthesis of prostaglandin H synthase. J. Clin. Invest. 82:1988;1877-1883.
7. Giri J.G., Ahdieh M., Eisenman J., Shanebeck K., Grabstein K., Kumaki S., Namen A., Park L.S., Cosman D., Anderson D. Utilization of the beta and gamma chains of the IL-2 receptor by the novel cytokine IL-15. EMBO J. 13:1994;2822-2830.
8. Gold M.R., DeFranco A.L. Biochemistry of B lymphocyte activation. Adv. Immunol. 55:1994;221-295.
9. Grant A.J., Roessler E., Ju G., Tsudo M., Sugamura K., Waldmann T.A. The interleukin-2 receptor (IL-2R): the IL-2R alpha subunit alters the function of the IL-2R beta subunit to enhance IL-2 binding and signaling by mechanisms that do not require binding of IL-2 to IL-2R alpha subunit. Proc. Natl. Acad. Sci. U.S.A. 89:1992;2165-2169.
10. Gu H., Maeda H., Moon J.J., Lord J.D., Yoakim M., Nelson B.H., Neel B.G. New role for shc in activation of the phosphatidylinositol 3-kinase-Akt pathway. Mol. Cell Biol. 20:2000;7109-7120.
11. Hank J.A., Surfus J.E., Gan J., Jaeger P., Gillies S.D., Reisfeld R.A., Sondel P.M. Activation of human effector cells by a tumor reactive recombinant anti-ganglioside GD2 interleukin-2 fusion protein (ch14.18-IL2). Clin. Cancer Res. 2:1996;1951-1959.
12. Hank J.A., Surfus J., Gan J., Albertini M., Lindstrom M., Schiller J.H., Hotton K.M., Khorsand M., Sondel P.M. Distinct clinical and laboratory activity of two recombinant interleukin-2 preparations. Clin. Cancer Res. 5:1999;281-289.
13. Hori T., Uchiyama T., Tsudo M., Umadome H., Ohno H., Fukuhara S., Kita K., Uchino H. Establishment of an interleukin-2-dependent human T cell line from a patient with T cell chronic lymphocytic leukemia who is not infected with human T cell leukemia/lymphoma virus. Blood. 70:1987;1069-1072.
14. Kimura Y., Takeshita T., Kondo M., Ishii N., Nakamura M., Van Snick J., Sugamura K. Sharing of the IL-2 receptor gamma chain with the functional IL-9 receptor complex. Int. Immunol. 7:1995;115-120.
15. Kondo M., Takeshita T., Ishii N., Nakamura M., Watanabe S., Arai K., Sugamura K. Sharing of the interleukin-2 (IL-2) receptor gamma chain between receptors for IL-2 and IL-4. Science. 262:1993;1874-1877.
16. Lenardo M.J. Interleukin-2 programs mouse alpha beta T lymphocytes for apoptosis. Nature. 353:1991;858-861.
17. Lentsch A.B., Nakagawa K., Yoshidome H., Gerassimides A., Miller F.N., Edwards M.J. Distinct biological activities of recombinant forms of human interleukin-2 in vivo. Cancer Immunol. Immunotherap. 43:1997;331-336.
18. Lo K.M., Sudo Y., Chen J., Li Y., Lan Y., Kong S.M., Chen L., An Q., Gillies S.D. High level expression and secretion of Fc-X fusion proteins in mammalian cells. Protein Eng. 11:1998;495-500.
19. Lode H.N., Xiang R., Pertl U., Forster E., Schoenberger S.P., Gillies S.D., Reisfeld R.A. Melanoma immunotherapy by targeted IL-2 depends on CD4(+) T-cell help mediated by CD40/CD40L interaction. J. Clin. Invest. 105:2000;1623-1630.
20. Margolin K.A. Interleukin-2 in the treatment of renal cancer. Semin. Oncol. 27:2000;194-203.
21. Mookerjee B.K., Pauly J.L. Mitogenic effect of interleukin-2 on unstimulated human T cells: an editorial review. J. Clin. Lab. Anal. 4:1990;138-149.
22. Moriggl R., Topham D.J., Teglund S., Sexl V., McKay C., Wang D., Hoffmeyer A., van Deursen J., Sangster M.Y., Bunting K.D., Grosveld G.C., Ihle J.N. STAT5 is required for IL-2-induced cell cycle progression of peripheral T cells. Immunity. 10:1999;249-259.
23. + T cells. Proc. Natl. Acad. Sci. U.S.A. 99:2002;8832-8837.
24. Nakamura M., Asao H., Takeshita T., Sugamura K. Interleukin-2 receptor heterotrimer complex and intracellular signaling. Semin. Immunol. 5:1993;309-317.
25. Nakamura Y., Russell S.M., Mess S.A., Friedmann M., Erdos M., Francois C., Jacques Y., Adelstein S., Leonard W.J. Heterodimerization of the IL-2 receptor beta- and gamma-chain cytoplasmic domains is required for signalling. Nature. 369:1994;330-333.
26. Nakarai T., Robertson M.J., Streuli M., Wu Z., Ciardelli T.L., Smith K.A., Ritz J. Interleukin 2 receptor gamma chain expression on resting and activated lymphoid cells. J. Exp. Med.180:1994;241-251.
27. Nelson B.H., Lord J.D., Greenberg P.D. Cytoplasmic domains of the interleukin-2 receptor beta and gamma chains mediate the signal for T-cell proliferation. Nature. 369:1994;333-336.
28. Noguchi M., Nakamura Y., Russell S.M., Ziegler S.F., Tsang M., Cao X., Leonard W.J. Interleukin-2 receptor gamma chain: a functional component of the interleukin-7 receptor. Science. 262:1993;1877-1880.
29. Opdenakker G., Rudd P.M., Wormald M., Dwek R.A., Van Damme J. Cells regulate the activities of cytokines by glycosylation. FASEB J. 9:1995;453-457.
30. Parmiani G., Rivoltini L., Andreola G., Carrabba M. Cytokines in cancer therapy. Immunol. Lett. 74:2000;41-44.
31. Perola O., Ripatti A., Pelkonen J. T-lymphocyte subpopulations do not express identical combinations of interleukin-2 receptor chains in the early phase of their activation and proliferation. Scand. J. Immunol. 52:2000;123-130.
32. Ravichandran K.S., Igras V., Shoelson S.E., Fesik S.W., Burakoff S.J. Evidence for a role for the phosphotyrosine-binding domain of Shc in interleukin-2 signaling. Proc. Natl. Acad. Sci. U.S.A. 93:1996;5275-5280.
33. Refaeli Y., Van Parijs L., London C.A., Tschopp J., Abbas A.K. Biochemical mechanisms of IL-2-regulated Fas-mediated T cell apoptosis. Immunity. 8:1998;615-623.
34. Robb R.J. Human interleukin-2. Methods Enzymol. 116:1985;493-525.
35. Robb R.J., Kutny R.M., Panico M., Morris H., DeGrado W.F., Chowdhry V. Post-translational modification of human T-cell growth factor. Biochem. Biophys. Res. Commun. 116:1983;1049-1055.
36. Robb R.J., Kutny R.M., Panico M., Morris H.R., Chowdhry V. Amino acid sequence and post-translational modification of human interleukin-2. Proc. Natl. Acad. Sci. U.S.A. 81:1984;6486-6490.
37. Russell S.M., Keegan A.D., Harada N., Nakamura Y., Noguchi M., Leland P., Friedmann M.C., Miyajima A., Puri R.K., Paul W.E.et al. Interleukin-2 receptor gamma chain: a functional component of the interleukin-4 receptor. Science. 262:1993;1880-1883.
38. Sereti I., Gea-Banacloche J., Kan M.Y., Hallahan C.W., Lane H.C. Interleukin-2 leads to dose-dependent expression of the alpha chain of the IL-2 receptor on CD25-negative T lymphocytes in the absence of exogenous antigenic stimulation. Clin. Immunol. 97:2000;266-276.
39. Smith K.A., Favata M.F., Oroszlan S. Production and characterization of monoclonal antibodies to human interleukin-2: strategy and tactics. J. Immunol. 131:1983;1808-1815.
40. Takeshita T., Asao H., Ohtani K., Ishii N., Kumaki S., Tanaka N., Munakata H., Nakamura M., Sugamura K. Cloning of the gamma chain of the human IL-2 receptor. Science. 257:1992;379-382.
41. Taniguchi T., Minami Y. The IL-2/IL-2 receptor system: a current overview. Cell. 73:1993;5-8.
42. Yodoi J., Teshigawara K., Nikaido T., Fukui K., Noma T., Honjo T., Takigawa M., Sasaki M., Minato N., Tsudo M. TCGF (IL-2)-receptor inducing factor(s). Part I. Regulation of IL 2 receptor on a natural killer-like cell line (YT cells). J. Immunol. 134:1985;1623-1630.
43. Yu T.K., Caudell E.G., Smid C., Grimm E.A. IL-2 activation of NK cells: involvement of MKK1/2/ERK but not p38 kinase pathway. J. Immunol. 164:2000;6244-6251.
44. Zanussi S., De Paoli P. The effects of interleukin-2 therapy on the viral reservoir in HIV+ patients. Biomed. Pharmacotherap. 54:2000;316-320.